SCHEMBL14924070

SCHEMBL14924070

CC(C)c1ccc(N2CCN(C(=O)CN(C)C)CC2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
ALDH1A1 P00352 4/20 0.46
KMT2A Q03164 4/20 0.46
LMNA P02545 3/20 0.46
NPY2R P49146 4/20 0.46
PIK3CD O00329 1/20 0.46
CSF1R P07333 1/20 0.46
CDK4 P11802 1/20 0.46
CDK6 Q00534 1/20 0.46
POLB P06746 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
DPP4 P27487 1/20 0.44
DPP9 Q86TI2 1/20 0.44
MEN1 O00255 3/20 0.44
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
TP53 P04637 1/20 0.43
GRM5 P41594 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14924432 0.85 KMT2A (0.53) MAPTALDH1A1KMT2ALMNAPOLB
SCHEMBL25839428 0.81 KDM4E (0.50) MAPTALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL14923975 0.80 SMN1; SMN2 (0.52) MAPTALDH1A1KMT2ALMNAPOLB
SCHEMBL6527041 0.76 NPY2R (0.39) ALDH1A1LMNANPY2RPIK3CDCSF1R
SCHEMBL13607124 0.73 KDM4E (0.56) MAPTALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL12160700 0.73 ALDH1A1 (0.53) MAPTALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL18068240 0.73 TSHR (0.59) MAPTALDH1A1KMT2ALMNAPOLB
SCHEMBL14924038 0.72 HSD17B10 (0.62) MAPTALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL12515923 0.72 ALDH1A1 (0.49) MAPTALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL14924062 0.72 HTR2A (0.50) MAPTALDH1A1POLBSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN MAPT 2828/4885ALDH1A1 3955/4885KMT2A 1857/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MAPT 2825/4885ALDH1A1 3912/4885KMT2A 1823/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 MAPT 2825/4885ALDH1A1 3912/4885KMT2A 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.